

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934  
(Amendment No.    )**

---

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under § 240.14a-12

**JUNO THERAPEUTICS, INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  - (1) Title of each class of securities to which transaction applies: \_\_\_\_\_
  - (2) Aggregate number of securities to which transaction applies: \_\_\_\_\_
  - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): \_\_\_\_\_
  - (4) Proposed maximum aggregate value of transaction: \_\_\_\_\_
  - (5) Total fee paid: \_\_\_\_\_
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  - (1) Amount Previously Paid: \_\_\_\_\_
  - (2) Form, Schedule or Registration Statement No.: \_\_\_\_\_
  - (3) Filing Party: \_\_\_\_\_
  - (4) Date Filed: \_\_\_\_\_

**JUNO THERAPEUTICS, INC.**  
**SUPPLEMENT TO NOTICE OF ANNUAL MEETING AND PROXY STATEMENT**

On April 24, 2017, Juno Therapeutics, Inc. ("Juno") filed with the Securities and Exchange Commission a definitive proxy statement (the "Proxy Statement") in connection with its 2017 Annual Meeting of Stockholders. The following supplemental information is being made available to Juno stockholders on May 25, 2017.

**Appointment of Jay T. Flatley to Board of Directors**

Effective May 22, 2017, the Board of Directors (the "Board") of Juno, upon recommendation from the nominating and governance committee of the Board, appointed Jay T. Flatley as a Class I director to fill a vacancy on the Board that was created by an increase in the authorized number of directors on the Board to 10. The Board also appointed Mr. Flatley to the audit committee of the Board, replacing Robert T. Nelsen on that committee.

Mr. Flatley, age 64, has served since July 2016 as Executive Chairman of Illumina, Inc., a global leader in DNA sequencing and array-based technologies, where he has been on the board of directors since October 1999. Mr. Flatley also served as Illumina's chief executive officer from December 2013 to July 2016 and as Illumina's president and chief executive officer from October 1999 through December 2013. Mr. Flatley also serves on the board of directors of Coherent, Inc. Mr. Flatley received a B.A. in economics from Claremont McKenna College and a B.S. and M.S. in industrial engineering from Stanford University. Juno's Board believes that Mr. Flatley's experience building a highly successful and innovative healthcare company at Illumina, where he oversaw the growth of annual revenue from just over \$1 million to more than \$2 billion and the growth of the organization from 20 employees to over 5,000, makes him an appropriate member for the Board.

The Board has determined that Mr. Flatley has no relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that he is "independent" as that term is defined under the rules of The Nasdaq Stock Market LLC ("NASDAQ"). The Board also determined that Mr. Flatley satisfies the independence standards for audit committee membership as established by applicable Securities and Exchange Commission and NASDAQ rules.

Neither Mr. Flatley nor any of his immediate family members has any direct or indirect material interest in any transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K.

In connection with his appointment, Mr. Flatley and Juno have entered into Juno's standard director indemnification agreement, the form of which was filed with the Securities and Exchange Commission on November 17, 2014 as Exhibit 10.18 to Juno's registration statement on Form S-1. Mr. Flatley will also receive compensation for his Board service pursuant to Juno's Non-Employee Director Compensation Policy.